Skip to search formSkip to main contentSkip to account menu

fradafiban

Known as: 5-((((4'-aminoiminomethyl)-(1,1'-biphenyl)-4-yl)oxy)methyl)-2-oxo-3-pyrrolidineacetic acid 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Biphenyl CompoundsPyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Platelet Glycoprotein IIb / IIIa Receptor Inhibitors – Role in Coronary Artery Disease
Gp IIb/IIIa receptor antagonists are potent antiplatelet agents since they block the final pathway in platelet aggregation… 
2001
2001
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
OBJECTIVE Lefradafiban is the orally active prodrug of fradafiban, a glycoprotein IIb/IIIa receptor antagonist. The present phase… 
2000
2000
Absorption of lefradafiban from different sites of the gastrointestinal tract.
AIMS Fibrinogen receptor antagonists show a close relationship between plasma concentrations and inhibitory effect. Optimal… 
1999
1999
Fradafiban. BIBU 52, BIBU 52 ZW.
1997
1997
Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
Experimental data suggest that formation of thromboxane A2 may be suppressed during administration of a glycoprotein IIb/IIIa… 
1997
1997
PK/PD simulations as a tool for rational design of clinical dosage regimens: an example with Fradafiban.
In clinical studies, pharmacodynamic effects should be achieved, e.g. maintenance of certain effects with reversibly acting drugs… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)